This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tripodi A et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41: 553–558
Hu KQ et al. (2001) Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 96: 1581–1586
Violi F et al. (1993) Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 17: 78–83
Youssef WI et al. (2003) Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 98: 1391–1394
Caldwell SH et al. (2004) Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 39: 592–598
Acknowledgements
The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Northup, P., Caldwell, S. How useful is ε-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis?. Nat Rev Gastroenterol Hepatol 3, 370–371 (2006). https://doi.org/10.1038/ncpgasthep0526
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0526
This article is cited by
-
Discreplasminin, a plasmin inhibitor isolated from Tityus discrepans scorpion venom
Archives of Toxicology (2009)